1. |
Arsh H, Manoj Kumar F, Simran F, et al. Role of PCSK9 inhibition during the inflammatory stage of SARS-COV-2: an updated review. Ann Med Surg (Lond), 2024, 86(2): 899-908.
DOI:10.1097/MS9.0000000000001601
|
2. |
Saputri FC, Azmi NU, Puteri MU, et al. High-Fat Diet Enhances Platelet Activation and Is Associated with Proprotein Convertase Subtilisin Kexin 9: An Animal Study. Nutrients, 2023, 15(20): 4463.
DOI:10.3390/nu15204463
|
3. |
Ishikawa H, Nagashima R, Kuno Y, et al. Effects of NKT Cells on Metabolic Disorders Caused by High-Fat Diet Using CD1d-Knockout Mice. Diabetes Metab Syndr Obes, 2023, 16: 2855-2864.
DOI:10.2147/DMSO.S428190
|
4. |
Chen PW, Tseng SY, Chang HY, et al. Diverse Effects of Cilostazol on Proprotein Convertase Subtilisin/Kexin Type 9 between Obesity and Non-Obesity. Int J Mol Sci, 2022, 23(17): 9768.
DOI:10.3390/ijms23179768
|
5. |
Ayoub C, Azar Y, Maddah D, et al. Low circulating PCSK9 levels in LPL homozygous children with chylomicronemia syndrome in a syrian refugee family in Lebanon. Front Genet, 2022, 13: 961028.
DOI:10.3389/fgene.2022.961028
|
6. |
Bouchard J, Malalgoda M, Storsley J, et al. Health Benefits of Cereal Grain- and Pulse-Derived Proteins. Molecules, 2022, 27(12): 3746.
DOI:10.3390/molecules27123746
|
7. |
Majeed ML, Ghafil FA, Fatima G, et al. Anti-Atherosclerotic and Anti-Inflammatory Effects of Curcumin on Hypercholesterolemic Male Rabbits. Indian J Clin Biochem, 2021, 36(1): 74-80.
DOI:10.1007/s12291-019-00858-5
|
8. |
Fedoryak O, Arama C, Diarra I, et al. Association of the rs562556 PCSK9 Gene Polymorphism with Reduced Mortality in Severe Malaria among Malian Children. Can J Infect Dis Med Microbiol, 2020, 2020: 9340480.
DOI:10.1155/2020/9340480
|
9. |
Drouin-Chartier JP, Tremblay AJ, Hogue JC, et al. Plasma PCSK9 correlates with apoB-48-containing triglyceride-rich lipoprotein production in men with insulin resistance. J Lipid Res, 2018, 59(8): 1501-1509.
DOI:10.1194/jlr.M086264
|
10. |
Chan DC, Watts GF, Somaratne R, et al. Comparative Effects of PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) Inhibition and Statins on Postprandial Triglyceride-Rich Lipoprotein Metabolism. Arterioscler Thromb Vasc Biol, 2018, 38(7): 1644-1655.
DOI:10.1161/ATVBAHA.118.310882
|
11. |
Eroğlu Z, Tetik Vardarlı A, Düzgün Z, et al. Case-control study on PCSK9 R496W (rs374603772) and D374Y (rs137852912) mutations in Turkish patients with primary dyslipidemia. Anatol J Cardiol, 2018, 19(5): 334-340.
DOI:10.14744/AnatolJCardiol.2018.86648
|
12. |
Hedayat AF, Park KH, Kwon TG, et al. Peripheral vascular atherosclerosis in a novel PCSK9 gain-of-function mutant Ossabaw miniature pig model. Transl Res, 2018, 192: 30-45.
DOI:10.1016/j.trsl.2017.10.007
|
13. |
Chen IC, Tseng WK, Li YH, et al. Effect of cilostazol on plasma levels of proprotein convertase subtilisin/kexin type 9. Oncotarget, 2017, 8(64): 108042-108053.
DOI:10.18632/oncotarget.22448
|
14. |
Zhang PY. PCSK9 as a therapeutic target for cardiovascular disease. Exp Ther Med, 2017, 13(3): 810-814.
DOI:10.3892/etm.2017.4055
|
15. |
Yu Z, Huang T, Zheng Y, et al. PCSK9 variant, long-chain n-3 PUFAs, and risk of nonfatal myocardial infarction in Costa Rican Hispanics. Am J Clin Nutr, 2017, 105(5): 1198-1203.
DOI:10.3945/ajcn.116.148106
|